Fig 1: mSSTR2 status of murine pheochromocytoma cells and tumors. (A) Western blot analyses of murine organs, tumors and cell cultures; (B) immunocytochemistry in MPC-mCherry cell cultures in vitro; bars: 30 µm; (C) immunohistochemistry on tissue sections of MPC-mCherry tumors; (left) overview of a tumor 4 weeks after cell injection, arrows indicate the absence of mSSTR2 in necrotic regions; bars: 1 mm; (right) membranous distribution of mSSTR2 in tumors; bars: 10 µm; (M) molecular weight of proteins in kDa; (nc) negative control in presence of blocking peptide (human SSTR2 fragment).
Fig 2: (A-D) Binding of somatostatin analogs to mSSTR2 on MPC-mCherry tumor sections. (A) mSSTR2 saturation binding analysis at increasing concentrations of the radioligand [64Cu]Cu-DOTATATE; non-specific binding was determined in presence of 5 µmol/L non-labeled DOTATATE; (B) Scatchard analysis of radioligand binding; (C) time-dependence of radioligand binding; (D) competition of radioligand with increasing concentrations of various SSTR2 agonists; (E-F) cellular uptake of [64Cu]Cu-DOTATATE in MPC-mCherry cell cultures at various temperatures; inhibition of radioligand uptake by co-incubation with various somatostatin agonists at 1 µmol/L; data are presented as means ± SEM; significance of differences was tested as compared to control; † p < 0.01; ‡ p < 0.001.
Supplier Page from Abcam for Somatostatin Receptor 2 peptide